<SEC-DOCUMENT>0001193805-19-000714.txt : 20190808
<SEC-HEADER>0001193805-19-000714.hdr.sgml : 20190808
<ACCEPTANCE-DATETIME>20190808070838
ACCESSION NUMBER:		0001193805-19-000714
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20190808
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20190808
DATE AS OF CHANGE:		20190808

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ADMA BIOLOGICS, INC.
		CENTRAL INDEX KEY:			0001368514
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				562590442
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36728
		FILM NUMBER:		191007436

	BUSINESS ADDRESS:	
		STREET 1:		C/O ADMA BIOLOGICS, INC.
		STREET 2:		465 STATE ROUTE 17
		CITY:			RAMSEY
		STATE:			NJ
		ZIP:			07446
		BUSINESS PHONE:		(201) 478-5552

	MAIL ADDRESS:	
		STREET 1:		C/O ADMA BIOLOGICS, INC.
		STREET 2:		465 STATE ROUTE 17
		CITY:			RAMSEY
		STATE:			NJ
		ZIP:			07446

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	R&R ACQUISITION VI, INC
		DATE OF NAME CHANGE:	20060707
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>e618590_8k-adma.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Report (Date of earliest event reported):
<U>August 8, 2019</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font: 18pt Times New Roman, Times, Serif"><B>ADMA BIOLOGICS, INC.</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact name of registrant as specified in its charter)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; width: 30%">&nbsp;</TD>
    <TD STYLE="text-align: center; width: 30%">&nbsp;</TD>
    <TD STYLE="text-align: center; width: 30%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Delaware</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-36728</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">56-2590442</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(State or other jurisdiction</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">of incorporation)</P></TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Commission</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">File Number)&nbsp;</P></TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(IRS Employer</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Identification No.)</P></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">465 State Route 17, Ramsey, New Jersey </FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">07446</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address of principal executive offices)</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Zip Code)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Registrant&rsquo;s telephone number, including
area code: <U>(201) 478-5552</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 100%; border-bottom: black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Former name or former address, if changed since last report.)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<I>see</I> General Instruction
A.2. below):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Wingdings">o</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Wingdings">&uml;</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Wingdings">&uml;</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Wingdings">&uml;</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities registered pursuant to Section 12(b) of the Act:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="3" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%; border: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Title of each class</FONT></TD>
    <TD STYLE="width: 20%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Trading Symbol(s)</FONT></TD>
    <TD STYLE="width: 40%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Name of each exchange on which registered</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Common stock, par value $0.0001 per share</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">ADMA</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Nasdaq Capital Market</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Indicate by check mark whether the registrant
is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (&sect;230.405 of this chapter)
or Rule 12b-2 of the Securities Exchange Act of 1934 (&sect;240.12b-2 of this chapter).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Emerging
growth company&nbsp;</FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&nbsp;</FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT><BR STYLE="clear: both"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 14%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Item 2.02.</B></FONT></TD><TD STYLE="width: 86%"><B>Results
                                         of Operations and Financial Condition.</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 8, 2019, ADMA Biologics, Inc.
issued a press release announcing its financial results for the three and six months ended June 30, 2019. A copy of the press release
is furnished herewith as Exhibit 99.1.*</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 14%"><B>Item 9.01.</B></TD><TD STYLE="width: 86%"><B>Financial Statements and Exhibits.</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(d) Exhibits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR>
    <TD STYLE="width: 14%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Exhibit No.</U></B></FONT></TD>
    <TD STYLE="width: 86%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Description</U></B></FONT></TD></TR>
<TR>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="e618590_ex99-1.htm" STYLE="-sec-extract: exhibit">ADMA Biologics, Inc. Press Release, dated August 8, 2019.</A></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">* The information in Item 2.02 of this
Form&nbsp;8-K shall not be deemed &ldquo;filed&rdquo; for purposes of Section&nbsp;18 of the Securities Exchange Act of 1934, as
amended (the &ldquo;Exchange Act&rdquo;), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated
by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by
specific reference in such a filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>SIGNATURE</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">August 8, 2019</FONT></TD>
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ADMA Biologics, Inc.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Brian Lenz</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;</FONT></TD>
    <TD STYLE="width: 30%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brian Lenz</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive Vice President and Chief Financial Officer</FONT></TD></TR>
</TABLE>


<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>e618590_ex99-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;&nbsp;</P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"><IMG SRC="image001.jpg" ALT="">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ADMA Biologics Reports Second Quarter
and First Half 2019 Financial Results</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">RAMSEY, N.J. and BOCA RATON, FL., &ndash; August 8, 2019 &ndash;
ADMA Biologics, Inc. (NASDAQ: ADMA) (&ldquo;ADMA&rdquo; or the &ldquo;Company&rdquo;), a vertically integrated commercial biopharmaceutical
and specialty immunoglobulin company that manufactures, markets and develops specialty plasma-derived biologics for the treatment
of immune deficiencies and the prevention of certain infectious diseases, today announced its financial results for the second
quarter and six months ended June 30, 2019, and provided an update on its recent achievements, operations and upcoming milestones.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;We are pleased with our significant accomplishments reported
during the second quarter of 2019, which include two United States Food and Drug Administration (&ldquo;FDA&rdquo;) approvals,
BIVIGAM&reg; and ASCENIV&trade;, as well as the FDA authorizations of product license transfers for BIVGAM&reg; and Nabi-HB&reg;,&rdquo;
stated Adam Grossman, ADMA&rsquo;s President and Chief Executive Officer. &ldquo;During the second quarter, we completed an equity
financing of approximately $52 million in gross proceeds, which we expect to use to support the commercial inventory build and
product launches for BIVIGAM&reg; and ASCENIV&trade;, expand the manufacturing capacity of our Boca Raton, FL facility, the procurement
of raw materials, plasma center expansion, other capital expenditures and for general corporate purposes.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Recent Achievements</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Obtained FDA approval for ASCENIV&trade; (formerly RI-002)</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Received FDA approval for BIVIGAM&reg;&rsquo;s prior approval supplement</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Raised $51.75 million of gross proceeds through equity financing</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Received FDA approval for license transfers for BIVIGAM&reg; and Nabi-HB&reg;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Expanded our sales and commercial team</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Anticipated Milestones</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Commercial launches and sales of BIVIGAM&reg; and ASCENIV&trade; in second half of 2019</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Expansion of our plasma collection network</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Financial Results for the Three Months Ended June 30, 2019</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ADMA reported total revenues of $6.6 million for the quarter
ended June 30, 2019, as compared to $4.7 million for the quarter ended June 30, 2018, representing an increase of $1.9 million,
or approximately 41%. The increase in revenues was primarily due to $2.4 million of contract manufacturing revenue in the second
quarter of 2019, with no corresponding amount in the second quarter of 2018, partially offset by a $0.5 million decrease in Nabi-HB&reg;
revenues related to the timing of shipment requests from a key customer. The contract manufacturing revenue is related to an agreement
we assumed from Biotest Pharmaceuticals Corporation (&ldquo;BPC&rdquo;). While we expect to generate additional revenue under this
contract during the second half of 2019, this contract is set to expire at the end of 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The consolidated net loss for the quarter ended June 30, 2019
was $13.2 million, or $(0.25) per basic and diluted share, as compared to a consolidated net loss of $14.7 million, or $(0.35)
per basic and diluted share, for the quarter ended June 30, 2018. The decrease in net loss of $1.5 million was primarily attributable
to higher revenues and lower plasma center operating costs as a result of having one plasma collection center in operation in 2019
as compared to three during the same period last year, partially offset by higher selling, general and administrative costs, comprised
of commercialization, marketing and prelaunch expenses for BIVIGAM&reg; and ASCENIV&trade;, as well as increased employee related
expenses, including stock-based compensation, and to increased interest expense. Included in the net loss for the quarter ended
June 30, 2019 were non-cash expenses of approximately $1.6 million for stock-based compensation, depreciation and amortization,
and non-cash interest expense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Financial Results for the Six Months Ended June 30, 2019</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ADMA reported total revenues of $10.1 million for the six months
ended June 30, 2019, as compared to $8.7 million for the six months ended June 30, 2018, representing an increase of $1.4 million,
or approximately 16%. The increase in revenues was primarily attributable to the $2.4 million of contract manufacturing revenue
generated during the second quarter of 2019, partially offset by a $0.9 million decrease in Nabi-HB revenues related to the timing
of shipment requests from a key customer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The consolidated net loss for the six months ended June 30,
2019 was $26.3 million, or $(0.53) per basic and diluted share, as compared to a consolidated net loss of $32.6 million, or $(0.74)
per basic and diluted share, for the six months ended June 30, 2018. The decrease in net loss of $6.3 million was primarily attributable
to higher revenues and lower manufacturing and plasma center operating costs, partially offset by higher selling, general and administrative
costs, comprised of commercialization, marketing and prelaunch expenses for BIVIGAM&reg; and ASCENIV&trade; as well as increased
employee related expenses, including stock-based compensation, in addition to a non-cash gain of $11.5 million from the transfer
of two of ADMA&rsquo;s plasma centers on January 1, 2019 as part of the consideration of the Biotest Therapy Business Unit (&ldquo;BTBU&rdquo;)
acquisition in June of 2017, largely offset by a loss on extinguishment of debt of $10.0 million related to the refinancing of
ADMA&rsquo;s senior secured notes and higher interest expense. Included in the net loss for the six months ended June 30, 2019
were non-cash expenses of approximately $3.3 million for stock-based compensation, depreciation and amortization, and non-cash
interest expense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">At June 30, 2019, ADMA had cash and cash equivalents of $73.6
million and accounts receivable of $5.1 million, as compared to $22.8 million and $1.4 million, respectively, at December 31, 2018.
ADMA&rsquo;s net working capital as of June 30, 2019 was $93.8 million, as compared to $34.9 million as of December 31, 2018. In
the second quarter of 2019, the Company completed an underwritten public offering of its common stock and received net proceeds
of $48.4 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>About
ADMA Biologics, Inc. (ADMA)</B></FONT><BR>
ADMA Biologics is a vertically integrated biopharmaceutical manufacturer with three FDA approved commercial specialty plasma-based
biologics. ADMA's mission is to develop and commercialize plasma-derived, human immune globulins targeted to niche patient populations
for the treatment and prevention of certain infectious diseases and management of immune compromised patient populations. The target
patient populations include immune compromised individuals who suffer from an underlying immune deficiency disease, or who may
be immune compromised for other medical reasons. ADMA has received U.S. Patents 9,107,906, 9,714,283, 9,815,886, 9,969,793 and
10,259,865 related to certain aspects of its products and product candidates. For more information, please visit www.admabiologics.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Primary Immune Deficiency Disease (&ldquo;PI&rdquo;)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PI is a class of inherited genetic disorders that causes an
individual to have a deficient or absent immune system. According to the World Health Organization, there are approximately 350
different genetic mutations encompassing PI. Some disorders present at birth or in early childhood, the disorders can affect anyone
regardless of age or gender. Some affect a single part of the immune system, others may affect one or more components of the system.
PI patients are vulnerable to infections and more likely to suffer complications from these infections as compared to individuals
with a normal functioning immune system. The infections may occur in any part of the body. Because patients suffering from PI lack
a properly functioning immune system, they typically receive monthly treatment with polyclonal immune globulin products. Without
this exogenous antibody replacement, these patients would remain vulnerable to persistent and chronic infections. PI has an estimated
prevalence of 1:1,200 in the United States, or approximately 250,000 people in the U.S.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About ASCENIV&trade; (Formerly referred to as RI-002)</B><BR>
ASCENIV&trade;, Immune Globulin Intravenous, Human &ndash; slra 10% Liquid, is a plasma-derived, polyclonal, intravenous immune
globulin (&ldquo;IVIG&rdquo;). &nbsp;ASCENIV&trade; is protected by U.S. Patents: 9,107,906, 9,714,283 and 9,815,886.&nbsp; ASCENIV&trade;
is manufactured using our unique, patented plasma donor screening methodology and tailored plasma pooling design, which blends
normal source plasma and plasma from donors tested using our proprietary microneutralization assay.&nbsp; ASCENIV&trade; contains
naturally occurring polyclonal antibodies.&nbsp; ASCENIV&trade; is indicated for the treatment of Primary Humoral Immunodeficiency
or Primary Immune Deficiency Disease (&ldquo;PI&rdquo;) in adults and adolescents (12 to 17 years of age). &nbsp;ADMA received
FDA approval for ASCENIV&trade; on April 1, 2019. Polyclonal antibodies are proteins that are used by the body's immune system
to neutralize microbes, such as bacteria and viruses and prevent against infection and disease. &nbsp;ASCENIV&trade; prevented
serious bacterial infection among fifty-nine patients treated for twelve months during the pivotal investigation.&nbsp; The most
common adverse reactions to ASCENIV&trade; (<FONT STYLE="font-family: Times New Roman, Times, Serif">&ge;</FONT>5% of study subjects)
were headache, sinusitis, diarrhea, gastroenteritis viral, nasopharyngitis, upper respiratory tract infection, bronchitis, and
nausea. &nbsp;ADMA anticipates the commercial launch of ASCENIV&trade; during the second half of 2019.&nbsp; Certain data and other
information about ASCENIV&trade; or ADMA Biologics and its products can be found on the Company&rsquo;s website at:&nbsp;<FONT STYLE="color: #0376BE">www.admabiologics.com</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About BIVIGAM&reg;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">BIVIGAM&reg; is an immune globulin intravenous (human), 10%
liquid, indicated for the treatment of primary humoral immunodeficiency. This includes, but is not limited to, X-linked and congenital
agammaglobulinemia, common variable immunodeficiency, Wiskott-Aldrich syndrome and severe combined immunodeficiency. These PIs
are a group of genetic disorders. Initially thought to be very rare, it is now believed that as many as 250,000 people in the U.S.
have some form of Primary Humoral Immunodeficiency (&ldquo;PI&rdquo;). BIVIGAM&reg; contains a broad range of antibodies similar
to those found in normal human plasma. These antibodies are directed against bacteria and viruses, and help to protect PI patients
against serious infections. BIVIGAM&reg; is a purified, sterile, ready-to-use preparation of concentrated human Immunoglobulin
(&ldquo;IgG&rdquo;) antibodies. Antibodies are proteins in the human immune system that work to defend against infections and disease.
FDA&rsquo;s initial approval for BIVIGAM&reg; was received by BPC in December 2012, and production of BIVIGAM&reg; was halted by
BPC in December 2016. ADMA obtained ownership and all rights, title and interest in BIVIGAM&reg; in June 2017 as part of the Biotest
Therapy Business Unit (&ldquo;BTBU&rdquo;) acquisition in June 2017 and resumed the production of BIVIGAM&reg; during the fourth
quarter of 2017. The FDA approved BIVIGAM&rsquo;s prior approval supplement to amend the biologics license application for the
product on May 9, 2019 allowing the Company to resume supplying BIVIGAM&reg; to the U.S. market. ADMA anticipates the commercial
launch of BIVIGAM&reg; during the second half of 2019.&nbsp; The FDA completed the license transfer for BIVIGAM&reg; to ADMA on
July 2, 2019. Certain data and other information about BIVIGAM&reg; or ADMA Biologics and its products can be found on the Company&rsquo;s
website at:&nbsp;<FONT STYLE="color: #0376BE">www.admabiologics.com</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Nabi-HB&reg;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Nabi-HB&reg;&nbsp;is a hyperimmune globulin that is rich in
antibodies to the Hepatitis B virus. Nabi-HB&reg; is a purified human polyclonal antibody product collected from plasma donors
who have been previously vaccinated with a Hepatitis B vaccine. Nabi-HB&reg; is indicated for the treatment of acute exposure to
blood containing Hepatitis B surface antigen (&ldquo;HBsAg&rdquo;), prenatal exposure to infants born to HBsAg-positive mothers,
sexual exposure to HBsAg-positive persons and household exposure to persons with acute Hepatitis B virus infection. Hepatitis B
is a potentially life-threatening liver infection caused by the Hepatitis B virus. It is a major global health problem and can
cause chronic infection and put people at high risk of death from cirrhosis and liver cancer. Nabi-HB&reg;&nbsp;has a well-documented
record of long-term safety and effectiveness since its initial market introduction. FDA approval for Nabi-HB&reg; was received
on March 24, 1999. Biotest acquired Nabi-HB&reg; from Nabi Biopharmaceuticals in 2007. ADMA obtained ownership and all rights,
title and interest in Nabi-HB&reg; in June 2017 as part of the BTBU acquisition and the FDA transferred the license to ADMA on
July 2, 2019. Certain data and other information about Nabi-HB&reg; or ADMA Biologics and its products can be found on the Company&rsquo;s
website at:&nbsp;<FONT STYLE="color: #0376BE">www.admabiologics.com</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Cautionary Note Regarding Forward-Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>This press release contains &quot;forward-looking statements&quot;
pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, about ADMA Biologics, Inc. (&quot;we&ldquo;,
&ldquo;our&rdquo; or the &ldquo;Company&rdquo;). Forward-looking statements include, without limitation, any statement that may
predict, forecast, indicate, or imply future results, performance or achievements, and may contain such words as &ldquo;estimate,&rdquo;
&ldquo;project,&rdquo; &ldquo;intend,&rdquo; &ldquo;forecast,&rdquo; &ldquo;target,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;plan,&rdquo;
&ldquo;planning,&rdquo; &ldquo;expect,&rdquo; &ldquo;believe,&rdquo; &ldquo;will,&quot; &ldquo;is likely,&rdquo; &ldquo;will likely,&rdquo;
&ldquo;should,&rdquo; &ldquo;could,&rdquo; &ldquo;would,&rdquo; &ldquo;may,&rdquo; or, in each case, their negative, or words or
expressions of similar meaning. These forward-looking statements also include, but are not limited to, statements concerning our
plans to develop, manufacture, market, launch and expand our own commercial infrastructure and commercialize our current products
and future products; the safety, efficacy and expected timing of, and our ability to, obtain and maintain regulatory approvals
of our current products; product expansions into new fields of use, indications and product candidates, and the labeling or nature
of any such approvals; our ability to successfully pursue commercialization and prelaunch activities for our products; the potential
of our specialty plasma-based biologics products and product candidates to provide meaningful clinical improvement for patients
living with Primary Immune Deficiency Disease or other indications; our ability to realize increased prices for plasma growth in
the plasma collection industry; and our expectations for future capital expenditures and requirements. Actual events or results
may differ materially from those described in this document due to a number of important factors. Current and prospective security
holders are cautioned that there also can be no assurance that the forward-looking statements included in this press release will
prove to be accurate. Except to the extent required by applicable laws or rules, ADMA does not undertake any obligation to update
any forward-looking statements or to announce revisions to any of the forward-looking statements. Forward-looking statements are
subject to many risks, uncertainties and other factors that could cause our actual results, and the timing of certain events, to
differ materially from any future results expressed or implied by the forward-looking statements, including, but not limited to,
the risks and uncertainties described in our filings with the U.S. Securities and Exchange Commission, including our most recent
reports on Form 10-K, 10-Q and 8-K, and any amendments thereto.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">COMPANY CONTACT:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Brian Lenz</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Executive Vice President and Chief Financial Officer | 201-478-5552
| www.admabiologics.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">INVESTOR RELATIONS CONTACT:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Jeremy Feffer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Managing Director, LifeSci Advisors, LLC | 212-915-2568 |</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ADMA BIOLOGICS, INC. AND SUBSIDIARIES<BR>
CONSOLIDATED STATEMENTS OF OPERATIONS<BR>
<BR>
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three Months Ended June 30,</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Six Months Ended June 30,</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold">REVENUES:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 40%; text-align: left; text-indent: 10pt">Product revenue</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 11%; text-align: right">6,525,233</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 11%; text-align: right">4,620,841</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 11%; text-align: right">10,018,114</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 11%; text-align: right">8,627,139</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 10pt">License revenue</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">35,709</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">35,709</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">71,417</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">71,417</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; text-indent: 20.1pt">Total Revenues</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">6,560,942</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">4,656,550</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">10,089,531</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">8,698,556</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">OPERATING EXPENSES:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 8.1pt">Cost of product revenue (exclusive of &nbsp;&nbsp;amortization expense shown below)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,491,236</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,645,662</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">19,896,415</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">21,888,410</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 10pt">Research and development</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">516,986</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,040,427</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,387,621</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,005,998</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 10pt">Plasma center operating expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">594,113</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,738,128</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,248,599</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,571,902</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 10pt">Amortization of intangible assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">211,234</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">211,234</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">422,469</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">422,469</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 10pt">Selling, general and administrative</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">6,086,047</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">5,438,480</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">11,681,517</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">10,759,661</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; text-indent: 20.1pt">Total operating expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">17,899,616</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">18,073,931</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">34,636,621</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">38,648,440</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">LOSS FROM OPERATIONS</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(11,338,674</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(13,417,381</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(24,547,090</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(29,949,884</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">OTHER INCOME (EXPENSE):</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 10pt">Interest and other income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">209,808</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">33,070</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">337,207</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">59,616</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 10pt">Interest expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,072,578</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,359,188</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,613,085</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,682,340</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 10pt">Loss on extinguishment of debt</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(9,962,495</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 10pt">Gain on transfer of plasma center assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11,527,421</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 10pt">Other (expense) income</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(10,428</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(4,332</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(21,785</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,635</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; text-indent: 20.1pt">Other expense, net</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,873,198</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,330,450</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,732,737</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(2,620,089</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">NET LOSS</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(13,211,872</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(14,747,831</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(26,279,827</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(32,569,973</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">BASIC AND DILUTED LOSS PER COMMON SHARE</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.25</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.35</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.53</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.74</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold">WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt; text-indent: 10.05pt">Basic and Diluted</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">52,206,204</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">42,712,168</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">49,295,805</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">44,007,409</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ADMA BIOLOGICS, INC. AND SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONDENSED CONSOLIDATED BALANCE SHEETS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center">June 30,</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center">December 31,</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold">ASSETS</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Unaudited)</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Current assets:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 50%; text-align: left; text-indent: 10pt">Cash and cash equivalents</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 11%; text-align: right">73,615,909</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 11%; text-align: right">22,754,852</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 10pt">Accounts receivable, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,086,663</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,392,441</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 10pt">Inventories</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">23,589,750</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">18,616,169</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 10pt">Prepaid expenses and other current assets</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,596,671</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,766,163</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 30pt">Total current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">103,888,993</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">44,529,625</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Property and equipment, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">29,444,489</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">30,115,730</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Intangible assets, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,581,943</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,004,412</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Goodwill</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,529,509</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,529,509</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Assets to be transferred under purchase agreement</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,153,508</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Restricted cash</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,000,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Deposits and other assets</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,829,186</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,543,737</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">TOTAL ASSETS</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">143,274,120</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">88,876,521</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">LIABILITIES AND STOCKHOLDERS' EQUITY</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Current liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 10pt">Accounts payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">6,788,144</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">5,900,394</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 10pt">Accrued expenses and other current liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,974,476</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,551,835</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 10pt">Current portion of deferred revenue</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">142,834</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">142,834</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 10pt">Current portion of lease obligations</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">223,114</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">29,983</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 20pt">Total current liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,128,568</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,625,046</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Senior notes payable, net of discount</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">67,468,637</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">26,440,830</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">End of term liability, notes payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,760,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Deferred revenue, net of current portion</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,332,949</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,404,365</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Subordinated note payable, net of discount</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14,890,711</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14,874,184</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Obligation to transfer assets under purchase agreement</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,621,844</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Lease obligations, net of current portion</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,414,976</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">119,080</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Other non-current liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">132,418</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">260,734</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">TOTAL LIABILITIES</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">96,368,259</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">69,106,083</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">COMMITMENTS AND CONTINGENCIES</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">STOCKHOLDERS' EQUITY</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Preferred Stock, $0.0001 par value, 10,000,000 shares authorized, no shares issued and outstanding</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Common Stock - voting, $0.0001 par value, 75,000,000 shares</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 10pt">authorized, 59,317,806 and 46,353,068 shares issued and outstanding</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,932</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,635</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Additional paid-in capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">289,616,994</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">236,203,041</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Accumulated deficit</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(242,717,065</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(216,437,238</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">TOTAL STOCKHOLDERS' EQUITY</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">46,905,861</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">19,770,438</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">143,274,120</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">88,876,521</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 B17AI9@  34T *@    @  0$2  ,
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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MS7W;^P'_ ,$D]%_:7^!4/C+QIJ_B#2?[6G<Z7!ILD,8:W7Y?,<R1/DLX; &
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M&?\ X-Y__BJ/^&U_B[_T4GQG_P"#>?\ ^*K]$/\ APM\+_\ H:/'W_@7:?\
MR-1_PX6^%W_0T>/O_ NT_P#D:OF_^(H< _\ 0*O_  5$^D_XACQW_P _G_X,
M?^9^> _;7^+F/^2D>-,_]A:?_P"*II_;6^+G_12/&?\ X-I__BJ^L?VM_P#@
MB7-\.?!4^O\ PUUS4-;_ +-@>:\TS52K7,RHK,S0O&BAFP !&5&><,20M<__
M ,$YO^"9'@O]L3X$W/BCQ!K7BC3[Z'59K$1:?- L12-8V!Q)"[;LL<\XZ<5[
MW^N' SRMYM"A!PC)1:5-<T6[VNO.SL]CP_\ 4_C..9+*IU)J<HN2O4?*TK7L
M[VTNM-SYO_X;7^+@'_)2/&G_ (-Y_P#XJ@_ML?%P_P#-2/&G_@WGX_\ 'J_0
MJZ_X(,_#/[-)Y/BKQTLNP["US:LH;'&1]G&1GMD?45^9'Q:^&>I_!CXFZYX5
MUA=FI:#>R6DNW.V3:?E=<_PLN&'LPKT.$<[X/XCJSHY=AX<T$FU*G%.STNM-
M?/M='G\59%Q9P_3A5S"M-1DVDU4;5UK9V>GD=:/VV/BYM_Y*3XT^G]KS_P#Q
M5"_MK_%P?\U(\:?^#>?_ .*K+_9G^!6H?M)?'+P_X,T]FBDUBY"SS@;OLUNO
MS32X[[4#$#N<#C.:_2(?\$&?AA_T-'CT?]O=I_\ (U9\6<0<'<.UXX7'X:'/
M)<UHTXO2]KO16OK;T-.%^'>+<_H2Q. K2<(NUW4:UM>RUZ:7/SQ;]M7XN9_Y
M*1XS_P#!O/\ _%4?\-K?%W/_ "4CQI_X-I__ (JO=O\ @I?_ ,$[?"/[%O@+
MPWJGAW5_$FHSZSJ+VDJZE-"Z(HC9P5$<2'.1W)^E?'7?BOH.&J7#>>X%9A@<
M+#DDVE>G%/1V>ECPN(7Q!DN-E@,;B)J<4F[3;6JNM;GIQ_;5^+A_YJ1XS_\
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M>UHI.,5N[JSUM9*]GV=C]N\%:.>YAF3QL\1/V$/BNVU)O:-G==;M]#TPC(%
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ML^W[LFT\.O\ LLN&'LPK^H/ WC+^T<L>4XF5ZM#;NX=/_ =O2W<_F?QLX/\
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M .S=XTD\3^!!!<;C-IK>268_?';\N1^%%<'^R+>R#Q+JD(B+1S0*[R#HK*V
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M2LH63VZPZ=&?-87B:E2Q.$K2@VJ--P:O:]W*[6_277JCO3^QI\6O^B9^./\
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MC_P-MO\ Y'H_X<5?"7_H->./_ VV_P#D>BBC_B(G$O\ T&U/_ F'_$.>&O\
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)W'4445U$G__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
